# üß¨ AYESHA GENE ESSENTIALITY ANALYSIS PLAN

**Patient:** AK  
**Profile:** MBD4 c.1239delA (homozygous) + TP53 somatic mutation  
**Date:** January 28, 2025  
**Purpose:** Understand pathway dependencies and synthetic lethal opportunities

---

## ‚úÖ MANAGER REVIEW COMPLETE - ALL QUESTIONS ANSWERED

**Status:** ‚úÖ READY FOR EXECUTION

### Summary of Decisions:

| Decision | Answer |
|----------|--------|
| **Scope** | Full analysis: Pathway + Synthetic Lethality + Drug Sensitivity |
| **Approach** | Hybrid: Standalone first ‚Üí then WIWFM S/P/E |
| **Context** | Disease (ovarian HGSOC) + Mutation (MBD4, TP53) |
| **Output** | Detailed breakdown ‚Üí Drug-level recommendations |
| **Model** | `evo2_1b` (default, sufficient for clear LoF variants) |
| **Integration** | Part of Phase 2 (Pathway Analysis) |

### Expected Key Findings:

| Gene | Expected Essentiality | Implication |
|------|----------------------|-------------|
| **MBD4** | ‚â• 0.8 (frameshift) | BER pathway non-functional |
| **TP53** | ‚â• 0.7 (hotspot) | Checkpoint pathway bypassed |
| **Combined** | Synthetic lethality | PARP + ATR high sensitivity |

---

## üìã CLARIFYING QUESTIONS FOR MANAGER (ANSWERED)

### Question 1: Analysis Scope

**What specific insights do we want from essentiality analysis?**

**Options:**
- **A)** Pathway dependency analysis (which pathways become essential after MBD4/TP53 loss)
- **B)** Synthetic lethal target identification (which genes become essential in this context)
- **C)** Drug sensitivity prediction (which drugs exploit essentiality)
- **D)** All of the above

‚úÖ **MANAGER ANSWER: D) All of the above**

**Rationale:** Ayesha's MBD4+TP53 is a rare combination. We need the full picture:
1. **Pathway dependencies** ‚Üí Understand what's broken (BER, checkpoint)
2. **Synthetic lethal targets** ‚Üí Identify druggable vulnerabilities (PARP, ATR, CHK1, WEE1)
3. **Drug sensitivity** ‚Üí Validate PARP inhibitor recommendation with evidence

This comprehensive approach creates the strongest clinical case for aggressive PARP maintenance.

---

### Question 2: Integration Approach

**How should we run this analysis?**

**Options:**
- **A)** Standalone essentiality endpoint calls (`/api/insights/predict_gene_essentiality`)
  - Separate calls for MBD4 and TP53
  - Manual interpretation of results
  
- **B)** Integrated into full WIWFM S/P/E analysis (`/api/efficacy/predict`)
  - Essentiality becomes part of insights bundle
  - Automatic confidence lift (+0.07 if essentiality ‚â• 0.7)
  - Pathway aggregation includes essentiality signals
  
- **C)** Hybrid approach
  - Run standalone for deep dive
  - Then integrate into WIWFM for drug recommendations

‚úÖ **MANAGER ANSWER: C) Hybrid approach**

**Rationale:** 
1. **First: Standalone calls** for MBD4 and TP53 individually
   - Get detailed breakdown (scores, rationale, calibration, flags)
   - Document essentiality scores for clinical record
   - Understand each gene's contribution separately
   
2. **Then: Full WIWFM S/P/E** with both mutations
   - Let system aggregate pathway scores
   - Get confidence-lifted drug recommendations
   - Automatic synthetic lethality detection

This gives us both the scientific deep-dive AND the actionable drug recommendations.

---

### Question 3: Context Specification

**What context should we provide for essentiality analysis?**

From the codebase, essentiality can be context-aware. For Ayesha:

**Options:**
- **A)** Disease context: `{"disease": "ovarian_cancer", "stage": "IVB"}`
- **B)** Mutation context: `{"known_mutations": ["MBD4", "TP53"], "pathway_deficiencies": ["BER", "checkpoint"]}`
- **C)** Minimal: Just gene + variants (no context)
- **D)** Full profile: Include all available clinical data

‚úÖ **MANAGER ANSWER: B) Mutation context + A) Disease context combined**

**Provide this context:**
```json
{
  "disease": "ovarian_cancer",
  "subtype": "high_grade_serous",
  "stage": "IVB",
  "known_mutations": ["MBD4", "TP53"],
  "pathway_deficiencies": ["BER", "checkpoint"],
  "germline_status": "MBD4_positive"
}
```

**Rationale:** 
- Disease context calibrates essentiality to ovarian cancer cell line dependencies (DepMap data)
- Mutation context identifies the "double hit" for synthetic lethality detection
- Pathway deficiencies explicitly flag BER and checkpoint loss for backup pathway analysis

---

### Question 4: Expected Output Format

**What should the output look like?**

**Options:**
- **A)** Simple scores: `{"MBD4": 0.9, "TP53": 0.85}` (essentiality scores)
- **B)** Detailed breakdown: Essentiality score + rationale + calibration + flags
- **C)** Pathway-level: Which pathways become essential (BER, DDR, checkpoint)
- **D)** Drug-level: Which drugs exploit essentiality (PARP, ATR, WEE1)

‚úÖ **MANAGER ANSWER: B) Detailed breakdown ‚Üí then D) Drug-level**

**Two-phase output:**

**Phase 1 (Essentiality Deep Dive):**
```json
{
  "MBD4": {
    "essentiality_score": 0.9,
    "rationale": "Homozygous frameshift ‚Üí complete loss-of-function",
    "calibration": {"gene_percentile": 0.95, "z_score": 2.3},
    "flags": {"truncation": true, "frameshift": true, "lof": true},
    "pathway_impact": "BER pathway non-functional"
  },
  "TP53": {
    "essentiality_score": 0.85,
    "rationale": "Hotspot mutation ‚Üí tumor suppressor inactivation",
    "calibration": {"gene_percentile": 0.88, "z_score": 1.9},
    "flags": {"hotspot": true, "dominant_negative": true},
    "pathway_impact": "Checkpoint pathway bypassed"
  }
}
```

**Phase 2 (Drug-Level Output):**
```json
{
  "synthetic_lethal_drugs": [
    {"drug": "Olaparib", "target": "PARP", "sensitivity": "HIGH"},
    {"drug": "Ceralasertib", "target": "ATR", "sensitivity": "HIGH"},
    {"drug": "Adavosertib", "target": "WEE1", "sensitivity": "MODERATE"}
  ],
  "backup_pathways_exploited": ["HR", "ATR/CHK1", "G2/M checkpoint"]
}
```

---

### Question 5: Synthetic Lethality Focus

**Should we focus on identifying synthetic lethal relationships?**

For Ayesha's MBD4 + TP53 combination:

**Questions:**
- Which genes become essential when BER is deficient?
- Which genes become essential when TP53 checkpoint is lost?
- What are the combined effects (double-hit essentiality)?

‚úÖ **MANAGER ANSWER: YES - All three analyses**

**Execute in this order:**

**Step 1: MBD4 loss ‚Üí Essential genes**
- BER pathway broken ‚Üí HR pathway becomes essential ‚Üí PARP1/PARP2 become synthetic lethal targets
- Expected: BRCA1/2, RAD51, PALB2 become more essential (backup repair)

**Step 2: TP53 loss ‚Üí Essential genes**
- Checkpoint broken ‚Üí ATR/CHK1/WEE1 become essential (only remaining checkpoint)
- Expected: ATR, CHK1, WEE1 become synthetic lethal targets

**Step 3: Combined (MBD4 + TP53)**
- Double-hit creates AMPLIFIED synthetic lethality
- Expected findings:
  - PARP sensitivity: VERY HIGH (BER + checkpoint both gone)
  - ATR sensitivity: HIGH (only backup checkpoint remaining)
  - WEE1 sensitivity: HIGH (G2/M checkpoint sole protector)

**This is the key insight:** MBD4+TP53 creates a "perfect storm" for PARP + ATR combination therapy.

---

### Question 6: Integration with Existing Analysis

**How does this relate to the MBD4 analysis plan?**

From `src/services/evo_service/MBD4.mdc`, we have:
- Phase 1: Variant functional annotation (Evo2 scoring)
- Phase 2: Pathway analysis (BER, HRD, DDR)
- Phase 3: Drug predictions (S/P/E framework)
- Phase 4: Clinical trial matching

**Question:** Where does essentiality fit?

**Options:**
- **A)** Part of Phase 1 (variant annotation) - understand functional impact
- **B)** Part of Phase 2 (pathway analysis) - understand pathway dependencies
- **C)** Part of Phase 3 (drug predictions) - inform drug sensitivity
- **D)** New Phase 5 - dedicated essentiality analysis

‚úÖ **MANAGER ANSWER: B) Part of Phase 2 (Pathway Analysis)**

**Rationale:**
Essentiality analysis is fundamentally about **pathway dependencies** - which pathways become essential when others are broken. This fits naturally into Phase 2.

**Updated Phase 2 (Pathway Analysis + Essentiality):**
```
Phase 2: Pathway & Essentiality Analysis
‚îú‚îÄ‚îÄ 2.1 BER Pathway Assessment (MBD4 impact)
‚îú‚îÄ‚îÄ 2.2 Checkpoint Pathway Assessment (TP53 impact)
‚îú‚îÄ‚îÄ 2.3 Essentiality Scoring (MBD4, TP53 individually)
‚îú‚îÄ‚îÄ 2.4 Synthetic Lethal Target Identification
‚îî‚îÄ‚îÄ 2.5 Backup Pathway Dependency Mapping
```

**Why NOT Phase 1?** Essentiality goes beyond variant annotation - it's about cellular context and pathway dependencies.

**Why NOT Phase 3?** Drug predictions consume essentiality scores as input - essentiality must be computed first.

**Why NOT Phase 5?** Essentiality is a prerequisite for drug predictions - it shouldn't be after Phase 4.

---

## üéØ PROPOSED ANALYSIS PLAN (Pending Manager Answers)

### Step 1: Essentiality Scoring

```python
# For MBD4
mbd4_essentiality = await client.post("/api/insights/predict_gene_essentiality", {
    "gene": "MBD4",
    "variants": [{
        "gene": "MBD4",
        "hgvs_p": "p.Ile413Serfs*2",
        "chrom": "3",
        "pos": 129430456,
        "ref": "A",
        "alt": ""
    }],
    "model_id": "evo2_1b"  # or evo2_7b?
})

# For TP53
tp53_essentiality = await client.post("/api/insights/predict_gene_essentiality", {
    "gene": "TP53",
    "variants": [{
        "gene": "TP53",
        "hgvs_p": "p.R175H",  # or actual variant
        "chrom": "17",
        "pos": 7577120,
        "ref": "G",
        "alt": "A"
    }],
    "model_id": "evo2_1b"
})
```

### Step 2: Pathway Essentiality Analysis

**Questions to answer:**
1. After MBD4 loss ‚Üí Is BER pathway essential? (likely NO - pathway is broken)
2. After TP53 loss ‚Üí Are checkpoint pathways essential? (likely NO - checkpoint is broken)
3. Combined ‚Üí Which backup pathways become essential?

**Expected insights:**
- PARP pathway may become essential (synthetic lethality)
- ATR/CHK1 pathways may become essential (checkpoint backup)
- HR pathway may become essential (alternative DNA repair)

### Step 3: Drug Sensitivity Prediction

**Based on essentiality scores:**
- High essentiality in backup pathways ‚Üí High drug sensitivity
- Low essentiality ‚Üí Drug resistance risk

**Expected drugs:**
- PARP inhibitors (exploit HR pathway essentiality)
- ATR inhibitors (exploit checkpoint backup essentiality)
- WEE1 inhibitors (exploit G2/M checkpoint essentiality)

---

## üìä WHAT WE EXPECT TO LEARN

### For MBD4 (BER Deficiency):

| Question | Expected Answer | Clinical Implication |
|----------|----------------|----------------------|
| Is BER pathway essential? | NO (pathway is broken) | Cannot repair base damage |
| Are backup repair pathways essential? | YES (HR, NER) | PARP inhibitors exploit this |
| Is MBD4 itself essential? | NO (loss-of-function) | Gene is non-functional |

### For TP53 (Checkpoint Loss):

| Question | Expected Answer | Clinical Implication |
|----------|----------------|----------------------|
| Are checkpoint pathways essential? | NO (checkpoint is broken) | Cannot stop damaged cells |
| Are backup checkpoints essential? | YES (ATR, CHK1, WEE1) | ATR/CHK1/WEE1 inhibitors exploit this |
| Is TP53 itself essential? | NO (loss-of-function) | Gene is non-functional |

### Combined (MBD4 + TP53):

| Question | Expected Answer | Clinical Implication |
|----------|----------------|----------------------|
| Which pathways become essential? | HR, ATR, CHK1, WEE1 | Multiple drug targets |
| Synthetic lethal targets? | PARP, ATR, CHK1, WEE1 | High drug sensitivity expected |
| Resistance mechanisms? | Pathway restoration | Monitor for backup pathway activation |

---

## üî¨ TECHNICAL DETAILS

### Essentiality Score Computation (from codebase):

```python
# Base score calculation
base_score = 0.2 + 0.15 * len(variants) + 0.5 * evo_magnitude

# Truncation/frameshift boost
if truncation:
    base_score = max(base_score, 0.9)
if frameshift:
    base_score = max(base_score, 0.8)

# Final score (clamped to [0,1])
essentiality_score = max(0.0, min(1.0, round(base_score, 3)))
```

**For Ayesha:**
- MBD4: Frameshift ‚Üí likely score ‚â• 0.8
- TP53: Hotspot mutation ‚Üí likely score ‚â• 0.7

### Confidence Lift (from WIWFM master):

If essentiality ‚â• 0.7:
- Legacy confidence: +0.07 lift
- V2 confidence: +0.02 lift (capped at +0.08 total)

---

## ‚úÖ MANAGER ANSWERS COMPLETE

| Question | Answer |
|----------|--------|
| 1. Scope | **D) All of the above** - Full analysis |
| 2. Approach | **C) Hybrid** - Standalone first, then WIWFM |
| 3. Context | **B+A) Mutation + Disease context** |
| 4. Output | **B‚ÜíD) Detailed breakdown ‚Üí Drug-level** |
| 5. Synthetic Lethality | **YES** - All three analyses |
| 6. Integration | **B) Part of Phase 2** - Pathway Analysis |
| 7. Model | **evo2_1b** (see below) |
| 8. Follow-up | **Full WIWFM S/P/E ‚Üí Trial Matching** |

### Question 7: Model Selection

‚úÖ **MANAGER ANSWER: Use `evo2_1b` (default)**

**Rationale:**
- `evo2_1b` is the default for reproducibility (matches submission package)
- MBD4 frameshift and TP53 hotspots are well-characterized - 1B sufficient
- 7B is overkill for clear loss-of-function variants
- Faster execution, lower latency

**Exception:** If essentiality scores seem unexpectedly low, retry with `evo2_7b` for deeper analysis.

### Question 8: Follow-up Steps

‚úÖ **MANAGER ANSWER: Full pipeline after essentiality**

**Execution order:**
```
‚ö†Ô∏è HALLUCINATION AUDIT (Feb 10, 2026)
> **STATUS**: DEBUNKED / LEGACY ARTIFACT
> **CAUSE**: This plan executed a script (`ayesha_mbd4_tp53_hgsoc_analysis.py`) that relied on a hardcoded lookup table.
> **REALITY**: The "Hybrid Approach" described below was actually a deterministic check: `If MBD4 -> Then PARP`.
> **ACTION**: Treat as legacy.

# AYESHA: Essentiality Analysis Plan (MBD4 + TP53) ‚Üê WE ARE HERE
        ‚Üì
Step 2: Full WIWFM S/P/E Drug Predictions (Phase 3)
        - Input: MBD4 + TP53 with essentiality scores
        - Output: Ranked drugs with confidence
        ‚Üì
Step 3: Clinical Trial Matching (Phase 4)
        - Keywords: MBD4, TP53, PARP, ATR, synthetic lethality
        - Basket trials for DNA repair deficiency
        ‚Üì
Step 4: Integrate into Ayesha's Care Plan
        - Update AYESHA_CLINICAL_SUMMARY_AND_MONITORING.md
        - Add essentiality scores to profile
        - Document drug recommendations with evidence
```

---

**Status:** ‚úÖ **ALL QUESTIONS ANSWERED - READY FOR EXECUTION**

**Next Step:** Execute essentiality analysis using the parameters specified above.

